Clinical trial · no report yet · Phase 3
POIESIS
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- NCT06479135 ↗
- Recruiting
- Kartos Therapeutics, Inc.
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 9 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis; Primary Myelofibrosis; MF
- Interventions
- Navtemadlin; Navtemadlin placebo; Ruxolitinib
- Arms
- Arm 1 · Experimental
- Arm 2 · Active comparator
- Enrollment
- 600 (estimated)
- Primary outcomes
- To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2
- To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2
- Sponsor
- Kartos Therapeutics, Inc.
- Start
- Jun 3, 2024
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06479135 · updated Sep 25, 2025